Short-term effect of sleeve gastrectomy on serum asprosin level in obese patients.

doi:10.3877/cma.j.issn.2095-9605.2020.04.004

Abstract

Abstract:

Objective

To investigate the short-term effect of laparoscopic sleeve gastrectomy (LSG) on serum asprosin level in obesity, and to analyze the correlation with clinical outcomes.

Methods

20 adults with obesity (BMI>35 kg/m²) receiving LSG at Department of Bariatric and Metabolic Surgery, The First Affiliated Hospital with Nanjing Medical University were included to this study between Nov 2017 and Oct 2018. Clinical measurements and laboratory determinations were performed before surgery and 3 months after surgery. The body composition indexes were measured by inbody770 and the biochemical indexes were measured by automatic biochemical analyzer. Homeostasis model assessment of insulin resistance index (HOMA-IR) was calculated. Fasting serum asprosin was analyzed by ELISA.

Results

3 months after LSG, mean total body weight decreased from (105.37±17.79) kg at baseline to (90.13±16.13) kg (P<0.001). The subjects showed a marked weight loss accompanied by significantly lower BMI values (pre, 37.85±4.64 kg/m², vs. post, 32.31±4.10 kg/m², P<0.001) after LSG. Meanwhile, insulin resistance improved remarkably after LSG as displayed by reductions in HOMA-IR levels (pre, 8.44±5.24 vs. post, 3.17±1.44, P<0.001). Serum fasting asprosin levels markedly reduced from 347.33 (267.25, 451.18) pg/mL to 254.95 (233.94, 311.88) pg/ml at 3 month after LSG (P<0.01). Multivariate analyses showed that the fasting serum asprosin was positively correlated with HOMA-IR (r=0.564, P=0.01) before LSG. Moreover, when assessing 3-months postoperative changes, a positive correlation was found between the variation of asprosin and the reduction of HOMA-IR (r=0.517, P=0.019). However, there was no association between asprosin and the changes of body weight, BMI, fasting glucose and blood lipids in our study.

Conclusions

Fasting serum asprosin in obesity was closely related to insulin resistance before surgery and reduced significantly in the short term after LSG. Moreover, the early change of asprosin was strongly associated with the improvement of insulin resistance. Asprosin may play an important role in insulin resistance, obesity and diabetes.

Key words: Obesity, Asprosin, Insulin resistance, Bariatric surgery, Sleeve gastrectomy

Ying Li, Zhenzhen Fu, Hongwen Zhou, Hui Liang, Wei Guan. Short-term effect of sleeve gastrectomy on serum asprosin level in obese patients.[J]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2020, 06(04): 227-232.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhfpydxbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-9605.2020.04.004

https://zhfpydxbdzzz.cma-cmc.com.cn/EN/Y2020/V06/I04/227

Figures/Tables 6

References 20

[1]	GBD 2015 Obesity Collaborators, Afshin A, Forouzanfar MH, et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years[J]. N Engl J Med, 2017, 377(1): 13-27.
[2]	GBD 2013 Risk Factors Collaborators, Forouzanfar MH, Alexander L, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2015, 386(10010): 2287-2323.
[3]	Chu Wan-Loy, Phang Siew-Moi. Marine Algae as a Potential Source for Anti-Obesity Agents[J]. Mar Drugs, 2016, 14(12): 222.
[4]	Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes[J]. N Engl J Med, 2012, 366(17): 1577-1585.
[5]	Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA, 2012, 307(1): 56-65.
[6]	Romere C, Duerrschmid C, Bournat J, et al. Asprosin, a fasting-induced glucogenic protein hormone[J]. Cell, 2016, 165(3): 566-579.
[7]	Greenhill C. Liver: Asprosin - new hormone involved in hepatic glucose release[J]. Nat Rev Endocrinol, 2016, 12(6): 312.
[8]	Hans PK, Guan W, Lin S, et al. Long-term outcome of laparoscopic sleeve gastrectomy from a single center in mainland China[J]. Asian J Surg, 2018, 41(3): 285-290.
[9]	Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome using two proposed definitions [J]. Diabetes Care, 2003, 26(3): 575-581.
[10]	Michael P. Czech. Insulin action and resistance in obesity and type 2 diabetes[J]. Nat Med. 2017, 23(7): 804-814.
[11]	Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States[J]. Ann N Y Acad Sci, 2013, 1281(1): 64-91.
[12]	Duerrschmid C, He Y, Wang C, et al. Asprosin is a centrally acting orexigenic hormone[J]. Nat Med, 2017, 23(12): 1444-1453.
[13]	Kajimura S. Adipose tissue in 2016: advances in the understanding of adipose tissue biology[J]. Nat Rev Endocrinol, 2017, 13(2): 69-70.
[14]	Wang Y, Qu H, Xiong X, et al. Plasma Asprosin Concentrations Are Increased in Individuals with Glucose Dysregulation and Correlated with Insulin Resistance and Insulin Secretion[J]. Mediators Inflamm, 2018, 2018: 9471583.
[15]	Zhang L, Chen C, Zhou N, et al. Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride[J]. Clin Chim Acta, 2019, 489: 183-188.
[16]	Wang CY, Lin TA, Liu KH, et al. Serum asprosin levels and bariatric surgery outcomes in obese adults[J]. Int J Obes, 2019, 43(5): 1019-1025.
[17]	Alan M, Gurlek B, Yilmaz A, et al. Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome[J]. Gynecol Endocrinol, 2019, 35(3): 220-223.
[18]	Acara AC, Bolatkale M, Kızıloğlu İ, et al. A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: Asprosin[J]. Am J Emerg Med, 2018, 36(8): 1504-1505.
[19]	Zhang Q, Ramracheya R, Lahmann C, et al. Role of KATP channels in glucose-regulated glucagon secretion and impaired counterregulation in type 2 diabetes[J]. Cell Metab, 2013, 18(6): 871-882.
[20]	Thorens B. Brain glucose sensing and neural regulation of insulin and glucagon secretion[J]. Diabetes Obes Metab, 2011, 13 (S1): 82-88.

指标	术前
年龄（岁）	28.55±6.69
性别（男：女）	5:15
体重（kg）	105.37±17.79
BMI（kg/m²）	37.85±4.64
高血压病（人/%）	7 (35%)
高脂血症（人/%）	8 (40%)
T2DM（人/%）	2 (10%)
IR（人/%）	17 (85%)
HbA1c（%）	5.92 ±1.06

指标	术前
年龄（岁）	28.55±6.69
性别（男：女）	5:15
体重（kg）	105.37±17.79
BMI（kg/m²）	37.85±4.64
高血压病（人/%）	7 (35%)
高脂血症（人/%）	8 (40%)
T2DM（人/%）	2 (10%)
IR（人/%）	17 (85%)
HbA1c（%）	5.92 ±1.06

指标	体重（kg）	BMI （kg/m²）	BF（kg）	PBF（%）	VFA（cm²）	腰围（cm）
术前	105.37±17.79	37.85±4.64	47.82±11.23	44.89±5.68	212.56±41.47	116.78±12.24
3月	90.13±16.13	32.31±4.10	40.14±10.68	42.41±5.90	190.64±45.15	103.38±13.68
P值	<0.001^a	<0.001^a	<0.001^a	0.014^a	<0.001^a	<0.001^a
指标	体重（kg）	臀围（cm）	WHR	BMR（kcal）	SBP（mmHg）	DBP（mmHg）
术前	105.37±17.79	119.37±8.30	1.01±0.05	1568.00(1487.75, 1799.75)	137.35±13.12	85.20±11.43
3月	90.13±16.13	110.55±9.11	0.99±0.06	1397.50(1315.50, 1656.25)	122.50±11.44	77.90±8.84
P值	<0.001^a	<0.001^a	0.001^a	<0.001^b	<0.001^a	0.006^a

指标	体重（kg）	BMI （kg/m²）	BF（kg）	PBF（%）	VFA（cm²）	腰围（cm）
术前	105.37±17.79	37.85±4.64	47.82±11.23	44.89±5.68	212.56±41.47	116.78±12.24
3月	90.13±16.13	32.31±4.10	40.14±10.68	42.41±5.90	190.64±45.15	103.38±13.68
P值	<0.001^a	<0.001^a	<0.001^a	0.014^a	<0.001^a	<0.001^a
指标	体重（kg）	臀围（cm）	WHR	BMR（kcal）	SBP（mmHg）	DBP（mmHg）
术前	105.37±17.79	119.37±8.30	1.01±0.05	1568.00(1487.75, 1799.75)	137.35±13.12	85.20±11.43
3月	90.13±16.13	110.55±9.11	0.99±0.06	1397.50(1315.50, 1656.25)	122.50±11.44	77.90±8.84
P值	<0.001^a	<0.001^a	0.001^a	<0.001^b	<0.001^a	0.006^a

指标	FPG(mmol/L)	FINS(pmol/L)	HbA1c(%)	HOMA-IR	TG(mmol/L)	TC(mmol/L)
术前	5.54±0.81	239.30 (115.40, 291.00)	5.80 (5.23, 6.08)	8.44 ±5.24	1.60±0.83	5.02 ±0.99
3月	5.07±0.72	80.80(59.45, 129.10)	5.00(4.90, 5.35)	3.17±1.44	1.25±0.35	4.21±0.97
P值	0.01^a	<0.001^b	<0.001^b	<0.001^a	0.075^a	<0.001^a
指标	LDL-C(mmol/L)	HDL-C(mmol/L)	ALT(U/L)	AST(U/L)	GGT(U/L)	asprosin(pg/ml)
术前	3.58 ±0.83	0.99 ±0.19	46.10 (19.45, 105.50)	39.82±25.92	29.75(20.53, 48.48)	347.33(267.25, 451.18)
3月	2.94±0.78	0.91±019	45.10(35.83, 67.00)	46.78±19.89	19.90(13.85, 27.43)	254.95(233.94, 311.88)
P值	0.001^a	0.060^a	0.247^b	0.196^a	0.009^b	<0.001^b

Please choose a citation manager

Content to export